Back to results
US 6,555,518 B1Granted
Gemcitabine as an immunosuppressive pharmaceutical agent
AssigneeEli Lilly and Company
InventorsRaimund Margreiter, Günther Konwalinka
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of a compound of the formula I wherein: R1 is a base defined by one of the formulae R2 is hydrogen, C1-C4 alkyl, bromo, fluoro, chloro or iodo; or a pharmaceutically-acceptable salt thereof for the manufacture of a medicament for immunosuppressive therapy of the human or animal body.
Claims10
A pharmaceutical composition comprising:
- (a) a compound of Formula I as follows:
- where:
- R1 is a base defined by one of the Formulae:
- R2 is hydrogen, C1-C4 alkyl, bromo, fluoro or iodo;
- or a pharmaceutically acceptable salt thereof;
- (b) one or more of the following:
- cyclosporin A, tacrolimus, mycophenolate mofetil, daclizumab, rapamycin and one of more corticosteroid(s);
- and
- (c) a pharmaceutically-acceptable carrier, diluent or excipient therefore.
6 more elements
The method of suppressing rejection of transplants in mammals comprising administering to said mammal a therapeutically effective amount of a compound of Formula I:
- where:
- R1 is a base defined by one of the Formulae:
- R2 is hydrogen, C1-C4 alkyl, bromo, fluoro or iodo;
- or a pharmaceutically acceptable salt thereof.
1 more element
The method of using a compound of Formula I in immunosuppressive therapy.
Dependencies are inferred from the claim text.